Dawn Halkuff - Aug 12, 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Director
Signature: /s/ Beth Hecht, Attorney-in-Fact
Stock symbol: XERS
Transactions as of: Aug 12, 2025
Transactions value $: -$309,226
Form type: 4
Date filed: 8/13/2025, 04:47 PM
Previous filing: Jun 4, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
HALKUFF DAWN	Director	C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO	/s/ Beth Hecht, Attorney-in-Fact	2025-08-13	0001743658

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Sale	-$309K	-42.5K	-26.98%	$7.28	115K	Aug 12, 2025	Direct	F1
holding	XERS	Common Stock						5.41K	Aug 12, 2025	By; DAWN HALKUFF REVOCABLE TRUST U/A DTD 08/25/2017	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.190 to $7.450, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2	The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Content

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.190 to $7.450, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.